RECRUITING

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment can be time-consuming and burdensome, leading to suboptimal use in clinical practice. Developed and endorsed by the American Society for Clinical Oncology (ASCO), the Practical Geriatric Assessment (PGA) is designed to improve clinical usability and adoption, but its implementation in real-world settings has not been evaluated. The PACE-70 study aims to evaluate PGA implementation and resultant chemotherapy dose modification among older adults with advanced cancer treated in a community setting. An exploratory aim will evaluate how the PGA, body composition (via abdominal computed tomography scan) and step count monitoring (via FitBit) correlate with chemotherapy toxicity and other clinical outcomes.

Official Title

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations for Older Adults With Cancer (PACE-70): A Hybrid Implementation-effectiveness Study

Quick Facts

Study Start:2025-07-01
Study Completion:2026-10-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06870617

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

William J Ferrell, MPH
CONTACT
2157468671
will.ferrell@pennmedicine.upenn.edu

Principal Investigator

Ramy Sedhom, M.D.
PRINCIPAL_INVESTIGATOR
Penn Princeton
Samuel Takvorian, M.D.
PRINCIPAL_INVESTIGATOR
Abramson Cancer Center

Study Locations (Sites)

Penn Medicine Princeton Medical Center
Princeton, New Jersey, 08540
United States
Lancaster General Hospital
Lancaster, Pennsylvania, 17602
United States
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: Abramson Cancer Center at Penn Medicine

  • Ramy Sedhom, M.D., PRINCIPAL_INVESTIGATOR, Penn Princeton
  • Samuel Takvorian, M.D., PRINCIPAL_INVESTIGATOR, Abramson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-01
Study Completion Date2026-10-01

Study Record Updates

Study Start Date2025-07-01
Study Completion Date2026-10-01

Terms related to this study

Keywords Provided by Researchers

  • PACE-70
  • Practical geriatric assessment
  • body composition in cancer
  • step count in cancer
  • Start low go slow

Additional Relevant MeSH Terms

  • Geriatric Assessment
  • Advanced Cancer
  • Toxicity